Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

NCT02793583 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

710

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic/Business Decision

Conditions

Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: Ublituximab
DRUG: Umbralisib
BIOLOGICAL: Bendamustine

Sponsor

TG Therapeutics, Inc.